175 related articles for article (PubMed ID: 38125722)
1. LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.
Nielsen M; Monberg T; Sundvold V; Albieri B; Hovgaard D; Petersen MM; Krarup-Hansen A; Met Ö; Camilio K; Clancy T; Stratford R; Sveinbjornsson B; Rekdal Ø; Junker N; Svane IM
Oncoimmunology; 2024; 13(1):2290900. PubMed ID: 38125722
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
[TBL] [Abstract][Full Text] [Related]
3. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS; Mullinax JE; Cox CA; Hall AM; Beatty MS; Blauvelt J; Innamarato P; Nagle L; Branthoover H; Wiener D; Schachner B; Martinez AJ; Richards AD; Rich CJ; Colón Colón M; Schell MJ; Teer JK; Khushalani NI; Weber JS; Mulé JJ; Sondak VK; Pilon-Thomas S; Sarnaik AA
Clin Cancer Res; 2022 Dec; 28(24):5317-5329. PubMed ID: 36215121
[TBL] [Abstract][Full Text] [Related]
4. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.
Finkelstein SE; Iclozan C; Bui MM; Cotter MJ; Ramakrishnan R; Ahmed J; Noyes DR; Cheong D; Gonzalez RJ; Heysek RV; Berman C; Lenox BC; Janssen W; Zager JS; Sondak VK; Letson GD; Antonia SJ; Gabrilovich DI
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):924-32. PubMed ID: 21398051
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
6. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
7. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
Seo YD; Lu H; Black G; Smythe K; Yu Y; Hsu C; Ng J; Hermida de Viveiros P; Warren EH; Schroeder BA; O'Malley RB; Cranmer LD; Loggers ET; Wagner MJ; Bonham L; Pillarisetty VG; Kane G; Berglund P; Hsu FJ; Mi X; Alexiev BA; Pierce RH; Riddell SR; Jones RL; Ter Meulen J; Kim EY; Pollack SM
JAMA Oncol; 2023 Dec; 9(12):1660-1668. PubMed ID: 37824131
[TBL] [Abstract][Full Text] [Related]
8. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.
Jebsen NL; Apelseth TO; Haugland HK; Rekdal Ø; Patel H; Gjertsen BT; Jøssang DE
J Med Case Rep; 2019 Jun; 13(1):177. PubMed ID: 31177991
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
11.
Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
Front Immunol; 2021; 12():610042. PubMed ID: 33679747
[TBL] [Abstract][Full Text] [Related]
12. Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
Spicer J; Marabelle A; Baurain JF; Jebsen NL; Jøssang DE; Awada A; Kristeleit R; Loirat D; Lazaridis G; Jungels C; Brunsvig P; Nicolaisen B; Saunders A; Patel H; Galon J; Hermitte F; Camilio KA; Mauseth B; Sundvold V; Sveinbjørnsson B; Rekdal Ø
Clin Cancer Res; 2021 May; 27(10):2755-2763. PubMed ID: 33542073
[TBL] [Abstract][Full Text] [Related]
13. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.
Mullinax JE; Hall M; Beatty M; Weber AM; Sannasardo Z; Svrdlin T; Hensel J; Bui M; Richards A; Gonzalez RJ; Cox CA; Kelley L; Mulé JJ; Sarnaik AA; Pilon-Thomas S
J Immunother; 2021 Feb-Mar 01; 44(2):63-70. PubMed ID: 33443972
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
15. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Zacharakis N; Huq LM; Seitter SJ; Kim SP; Gartner JJ; Sindiri S; Hill VK; Li YF; Paria BC; Ray S; Gasmi B; Lee CC; Prickett TD; Parkhurst MR; Robbins PF; Langhan MM; Shelton TE; Parikh AY; Levi ST; Hernandez JM; Hoang CD; Sherry RM; Yang JC; Feldman SA; Goff SL; Rosenberg SA
J Clin Oncol; 2022 Jun; 40(16):1741-1754. PubMed ID: 35104158
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
18. T Cells Expanded from PD-1
Li T; Zhao L; Yang Y; Wang Y; Zhang Y; Guo J; Chen G; Qin P; Xu B; Ma B; Zhang F; Shang Y; Li Q; Zhang K; Yuan D; Feng C; Ma Y; Liu Z; Tian Z; Li H; Wang S; Gao Q
Cancer Res; 2021 Apr; 81(8):2184-2194. PubMed ID: 33408117
[TBL] [Abstract][Full Text] [Related]
19. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
20. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
Zhu Y; Zhou J; Zhu L; Hu W; Liu B; Xie L
Hum Vaccin Immunother; 2022 Nov; 18(5):2060019. PubMed ID: 35468048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
